The year in cardiology 2016: valvular heart disease

A large number of studies addressing various aspects of the diagnosis and treatment of valvular heart disease (VHD) have been published since the ESC Annual congress in 2015. As expected in this era of rapidly evolving therapeutic modalities and technologies, many scientific contributions are related to the expanded role of percutaneous interventions. New data are now available, consolidating the validity of the transcatheter approach in a variety of subsets of patients and therefore offering new strategies and perspectives in management. The most relevant articles have been selected for this review. It is well known that ageing of the population is associated with a higher prevalence of VHD. UK population projections of diagnosed and undiagnosed significant valvular heart disease. The OxValve Population Cohort Study. Diagnosed estimates are based on the number excluded from participation in the present study due to a prior diagnosis of valvular heart disease. Undiagnosed estimates are based on the number with newly diagnosed significant valvular heart disease in OxVALVE-PCS. Reproduced with permission from D’Arcy JL et al.1 The mechanisms responsible for aortic valve calcification and development of aortic stenosis (AS) have been explored, and an association between valvular iron resulting from intraleaflet haemorrhage and the degree of aortic valve calcification has been demonstrated.2 Iron uptake by valvular interstitial cells produces proliferation and extracellular matrix remodelling leading to calcification and progressive narrowing of the valve. These findings emphasize the pathophysiological role of valvular haemorrhages and suggest iron transporters as a novel potential therapeutic target to slow the haemodynamic progression of AS. Some subsets of patients with AS deserve special consideration and may require different patterns of treatment. An analysis of the Duke Echocardiographic Database revealed that in patients with moderate/severe AS and left ventricular dysfunction mortality was definitely substantial and aortic valve surgery was associated with a significant survival benefit even in the presence of only moderate AS (mean gradient >25 and <40 mmHg).3 In this high-risk cohort transcatheter aortic valve implantation (TAVI) rather than aortic valve replacement (AVR) may well be a convenient option in the future. Asymptomatic patients with severe mixed aortic valve disease should be evaluated at least every 6 months because half of them will become symptomatic and require AVR within 1 year.4 Therefore, more liberal indication criteria for AVR should be adopted in the mixed aortic valve disease population. Following the advent of TAVI, the treatment of AS has changed dramatically, and new perspectives are expected in the future. Transcatheter aortic valve implantation is currently considered the treatment of choice for inoperable patients and the preferred alternative for high-risk patients. The long-term superiority of TAVI in high-risk patients has been recently reemphasized.5 A total of 750 patients were randomly assigned to, and underwent, TAVI with a self-expandable device (CoreValve) or surgical AVR. After 3 years, TAVI was associated with significantly reduced all-cause mortality or stroke (37.3% vs 46.7%: P = 0.006) and better aortic valve haemodynamics compared with surgery. Recently, scientific evidence has been provided to support the idea that TAVI is non-inferior to surgery in elderly patients at intermediate-risk patients. In the PARTNER 2 randomized trial,6 1011 intermediate-risk patients were assigned to TAVI (SAPIEN XT; Edwards Lifesciences) and 1021 to surgical AVR. At 2 years no significant differences were observed between the two groups in the primary end point of all-cause mortality or stroke. Of note, in the cohort of patients who received transfemoral implantation, TAVI was associated with a significantly lower rate of all-cause death or disabling stroke compared with surgical AVR. In another study,7 the latest generation SAPIEN 3 device (Edwards Lifesciences) was evaluated in 1077 intermediate-risk patients. Using a propensity score analysis, with the inherent limitations of this method, the outcomes in this population were compared with those observed in intermediate-risk patients treated with surgical AVR in the PARTNER 2 trial. At 1 year follow-up, inpatients treated with the SAPIEN 3, all-cause mortality was 7.4%, the occurrence of disabling stroke 2%, aortic valve re-intervention 1%, and moderate or severe paravalvular regurgitation 2%. Comparison with the surgical group revealed that for the primary composite endpoint of mortality, strokes, re-interventions and moderate or severe aortic regurgitation at 1 year, TAVI with SAPIEN 3 was superior to surgical AVR. These findings support the extension of the clinical indications of TAVI to elderly patients at intermediate risk with severe AS. A further extension of the indications of TAVI toward low risk patient is to be studied in a dedicated RCT: PARTNER 3 and Evolut low risk. Random-effects meta-analysis of transcatheter aortic valve implantation vs. surgical aortic valve replacement for the primary outcome of death from any cause. Forest plots showing the results of meta-analysis of transcatheter aortic valve implantation vs. surgical aortic valve replacement for the primary outcome of death from any cause at 2 years of follow-up. Hazard ratio estimates according to intention-to-treat principle were retrieved from three trials (PARTNER 1A, NOTION, and PARTNER 2A); whereas one trial (US CoreValve High Risk) contributed with the estimated risk ratio by using the events provided in as-treated populations. The provided number of events and total trial population in each arm correspond to intention-to-treat or as-treated populations, according to the available information in each trial. Boxes and horizontal lines represent the respective hazard ratio and 95% confidence interval for each trial. The vertical solid line on the plot represents the point estimate of hazard ratio = 1. The vertical dashed line on plot represents the point estimate of overall hazard ratio. The size of each box is proportional to weight of that trial result. Diamonds represent the 95% confidence interval for pooled estimates of the effect and are centred on pooled hazard ratios. Heterogeneity estimate of τ2 accompanies the summary estimate. Values of τ2 around 0.04 are considered to indicate low heterogeneity. TAVI, transcatheter aortic valve implantation; SAVR, surgical aortic valve replacement; HR, hazard ratio; CI, confidence interval. Reproduced with permission from Siontis GC et al.8 Important information on the long-term outcome after TAVI was reported in the large FRANCE-2 registry9 showing that valve performance remains stable over time and late mortality is largely related to non-cardiac causes. However, information regarding the durability of bioprostheses used in TAVI is still limited. Hypo attenuated thickening of valve leaflets after Transcatheter valve implantation. Reconstructions of a contrast-enhanced retrospectively electrocardiogram-gated post-transcatheter aortic valve implantation computed tomography angiography of an 80 year-old female (A and B) revealing subtle early hypo-attenuated thickening of the acoronary leaflet of an SAPIEN 3 prosthesis. Due to the clinical circumstances, the patient was only continued on single-antiplatelet therapy with aspirin. After 3-month follow-up computed tomography angiography revealed progression with up to 5 mm thickening of the non-coronary and additionally the right coronary cusp with restricted leaflet motion. The patient received a modified therapy with a combination of clopidogrel and phenprocoumon. Following further 3-month repeat computed tomography angiography showed almost complete disappearance of the hypo-attenuated thickening and resolution of leaflet rigidity . Reproduced with permission from Pache G et al.10 A large multicentric registry identified predictors of endocarditis after TAVI and showed that patients who developed endocarditis had high rates of in-hospital mid-term mortality.11 Finally, a large international registry initiated by the ESC: ROPAC on pregnancy in patients with cardiac disease, showed that the overall fatality rate in pregnant women with moderate or severe AS is low. However, the presence of severe symptomatic AS carries a substantial risk of heart failure and is associated with high rates of hospitalization which highlights the importance of appropriate patient evaluation and counselling prior to conception.12 Aortic regurgitation (AR) can result from degeneration of a previously implanted bioprosthesis. This situation in high-risk patients can be conveniently treated with transcatheter aortic valve-in-valve implantation. An encouraging 8-year single-centre experience with this procedure has been recently reported in a large number of patients with failed aortic bioprosthesis.13 Haemodynamically significant AR due to paravalvular leak is occasionally observed after aortic valve replacement. It can lead to heart failure and haemolysis, and may increase the risk of endocarditis. Percutaneous closure with plugs improves patient prognosis, is potentially associated with less mortality and morbidity than reoperation, and may be considered in selected high-risk patients.14 A large series of patients submitted to primary mitral repair for isolated degenerative mitral regurgitation (MR) over 1 decade was analysed and the effect of recurrent MR was evaluated.15 The 15-year incidence of recurrent moderate or greater MR was 13.3%, and the incidence of mitral reoperation was 6.9%. Important determinants of recurrent MR were: age, mild intraoperative residual MR, anterior leaflet prolapse, bileaflet prolapse and lack of annuloplasty. Recurrence of moderate or greater MR was associated with adverse left ventricular remodelling and increased likelihood of death. A number of important scientific contributions dealing with secondary MR have been published. Left ventricular systolic function has been assessed in a large series of patients with non-ischaemic dilated cardiomyopathy, with or without severe secondary MR, using left ventricular ejection fraction and speckle tracking global longitudinal strain.16 This latter methodology revealed a more deteriorated intrinsic myocardial function in patients with severe secondary MR, compared with patients without significant MR, in spite of equivalent ejection fraction. The 2-year outcomes of a randomized trial comparing mitral valve repair with mitral valve replacement with preservation of the whole subvalvular apparatus, in patients with severe ischaemic MR have been reported.17 No significant difference in left ventricular reverse remodelling or survival was observed. The rate of recurrence of moderate or severe MR at 2 years was higher in the repair group than in the replacement group (58.8% vs 3.8%, P< 0.001). As a consequence, patients in the repair group had more serious adverse events related to heart failure (P = 0.05) and more cardiovascular readmissions (P = 0.01). The 2-year outcomes of another randomized trial comparing coronary artery by-pass grafting (CABG) alone with CABG plus mitral valve repair in patients with moderate ischaemic MR have been reported.18 After 2 years, the mean left ventricular end-systolic volume index was not significantly different between the two groups. Mortality was also similar (10.6% vs 10.0%, P = 0.78). Combined surgery was associated with improvement in the rate of moderate or severe residual MR (11.2% vs 32.3%, P < 0.001), but also with a higher rate of neurological events and supraventricular arrhythmias. As the population continues to age, the incidence of hemodynamically significant MR is expected to rise, and transcatheter interventions will play an expanded role. Edge to edge repair with the MitraClip device is currently by far the most commonly used percutaneous procedure to correct MR in anatomically suitable high-risk or inoperable patients. The 5-year results of the EVEREST II randomized trial comparing the percutaneous edge to edge repair technique with conventional surgery have been reported.19 At 5 years, the rate of the composite endpoint of freedom from death, surgery, or 3+ or 4+ MR was 44.2% in the percutaneous repair group and 64.3% in the surgical group (P = 0.01). The difference was driven by increased rates of 3+ or 4+ MR and need for surgery in the percutaneous repair group. Following the percutaneous procedure, 78% of surgeries occurred within the first 6 months. Beyond 6 months, rates of surgery and moderate-to-severe MR were equivalent between groups. Five-year mortality was not significantly different for percutaneous repair and surgery, respectively 20.8% and 26.8% (P = 0.4). The German transcatheter mitral valve interventions (TRAMI) registry prospectively enrolled 828 patients submitted to MitraClip therapy (median age 76 years, and median logistic EuroSCORE I: 20.0%). One-year outcomes, available in 90.5% of the entire registry population, have been published.20 One year mortality was 20.3%. By multivariate analysis, predictors of death at 1 year were identified: NYHA class IV, anaemia, previous aortic valve intervention, serum creatinine >1.5 mg/dL, peripheral artery disease, left ventricular ejection fraction <30%, severe tricuspid regurgitation and procedural failure. Quality of life improved remarkably after MitraClip implantation. Importantly, a significant proportion of patients regained complete independence in self-care. The efficacy of percutaneous edge to edge repair, as well as its impact on the natural history, is strongly dependent on the acute reduction of MR. Residual 2+ MR immediately after MitraClip implantation is associated with more unfavourable outcomes (survival, symptom relief, and recurrence of MR) during follow-up compared with residual 1+ or less MR.21 The absence of mitral valve annuloplasty is a concern regarding the durability of MitraClip treatment. Furthermore, some patients are not eligible for MitraClip therapy due to excessive annular dilatation. In well-selected patients, annuloplasty alone can completely eliminate or at least remarkably reduce MR. Therefore, the introduction of a reliable annuloplasty device into the percutaneous armamentarium of mitral valve repair definitely offers new perspectives in the field of transcatheter mitral interventions. Early results obtained with the Cardioband system, a direct, adjustable annuloplasty device, in 31 high-risk patients with moderate-to-severe or severe secondary MR have been reported.22 Following Cardioband adjustment (29 of 31 patients), MR was none or trace in six patients (21%), mild in 21 (72%), and moderate in 2 (7%). Procedural mortality was zero and in-hospital death (neither procedure nor device-related) occurred in two patients. Another method of direct percutaneous annuloplasty, performed with the Mitralign system, has been investigated in 71 high-risk patients with moderate to severe secondary MR.23 The procedure appeared to be feasible and safe. In addition, left ventricular reverse remodelling and significant clinical improvement have been documented during a 6-month follow-up. Transcatheter mitral valve replacement in native mitral valve disease represents a rapidly moving field of great interest for the cardiological community. Encouraging early clinical experiences with different devices are presently ongoing worldwide, and results in consistent clinical series are expected to be published in the near future. The importance of multimodality imaging will also be a key factor for the selection of patients and planning of the procedure.24 Pre-operative pulmonary hypertension has been shown to affect the long-term outcome in a large series of patients operated on for mitral stenosis (MS).25 Ten-year survival after mitral valve surgery was significantly lower in the moderate-severe pulmonary hypertension group, compared with the normal pulmonary artery pressure-mild pulmonary hypertension group (58% vs 83%; P = 0.001). According to this finding, patients with MS and mild pulmonary hypertension should be considered for mitral valve surgery. A multicentre retrospective review of clinical outcomes of 64 patients with MS and severe mitral annular calcification submitted to transcatheter mitral valve replacement using balloon-expandable TAVI valves was performed.26 Access was transatrial in 15.6%, transapical in 43.8% and transseptal in 40.6%. In this preliminary experience, the procedure was associated with significant adverse events, and 30-day all-cause mortality was 29.7%. Obviously, only very symptomatic patients with limited therapeutic options should be considered for this modality of treatment at this stage. Following the recommendations of the European and American Guidelines for the management of VHD, tricuspid regurgitation (TR) should be addressed early in the disease process to prevent the development of right-sided heart failure. A recent study showed that in patients with moderate TR or tricuspid annular dilatation undergoing mitral valve repair, concomitant tricuspid annuloplasty was safe, effective and associated with improved long-term right-sided remodelling.27 Tricuspid annuloplasty can either be carried out with suturing techniques or with the implantation of prosthetic rings. Controversy remains regarding the effectiveness of one method compared with the other. No difference in patient survival, late functional status, progression of TR or tricuspid valve reoperations has been found in a recent retrospective study comparing patients treated with suture annuloplasty and those submitted to ring annuloplasty.28 Both techniques have been shown to yield good results. Suture annuloplasty can be performed easily and rapidly with a lower cost compared with ring annuloplasty which requires a commercially available prosthetic device. When isolated severe TR occurs in a context of right heart failure or develops late following left-sided valve surgery, the surgical risk is generally high. In these settings percutaneous therapeutic options to correct or at least reduce TR are badly needed. Although the clinical experiences with new procedures and devices are quite preliminary, some important attempts and contributions in this field have to be recognized. The TriCinch device allows transfemoral fixation of a corkscrew in the annulus of the tricuspid valve in proximity to the antero-posterior commissure. Following deployment of a self-expandable nitinol stent in the inferior vena cava, appropriate traction is exerted and the antero-posterior diameter of the valve is reduced with improvement of leaflet coaptation.29 Tricuspid regurgitation can also be treated with edge-to-edge repair using the MitraClip system.30 Another device used to reduce TR is the FORMA System, which is a valve spacer/occluder positioned within the tricuspid orifice, creating a platform for native leaflet coaptation to reduce the regurgitant jet.31 Feasibility and safety of these procedures have been demonstrated, but the experience is limited and more data are necessary to assess their efficacy. In total there was a lot of new evidence in the domain of VHD during the past year and it is expected that it will be incorporated into the upcoming ESC/EACTS on VHD to be published next year. Conflict of interest: Prof. Alfieri has no conflicts of interest to declare. Prof. Vahanian declares the following conflict of interest — Consultancy for Edwards Lifesciences, Abbott Vascular and Valtech Cardio.